公开(公告)号：EP2547672A1

公开(公告)日：2013-01-23

申请号：EP11710373.9

申请日：2011-03-15

申请人： Aventis Pharmaceuticals Inc.

发明人： HARRIS, Keith J. ,  AGUIAR, Joacy C. ,  SHUM, Patrick Wai-Kwok ,  ZHAO, Zhicheng ,  POLI, Gregory B. ,  STOKLOSA, Gregory ,  CHOI-SLEDESKI, Yong-Mi ,  REILING, Stephan ,  STEFANY, David ,  GARDNER, Charles

IPC分类号： C07D403/04 ,  A61K31/505 ,  A61P11/00

CPC分类号： C07D403/04

摘要： The present invention is directed to a substituted pyrimidine compound of formula (I) as set forth herein, or an enantiomer thereof, or a prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such a compound. The invention also includes a method of treatment of a patient by the administration of a pharmaceutically effective amount of such a compound. Formula (I), wherein m and n, independently of each other, are selected from the integers 0, 1, 2 or 3; X and Y, independently of each other, are selected from CR
1 R
2 , NR
1 or O, wherein X and Y cannot both be O; or X and Y, taken together with the bond between them, form a phenyl group optionally substituted by one to four R
3 groups; each Z, independently of each other, is CR
1 R
2 ; R
1 , R
2 and R
3 , independently of each other, are selected from the group consisting of H, halogen, aryl, amino, optionally substituted alkyl, optionally substituted alkoxy, and carboxy; wherein optionally substituted alkyl, may be substituted by one to three of the same or different of halogen, carboxy, cyano, hydroxy, amino or aryl.

公开(公告)号：EP2547673A1

公开(公告)日：2013-01-23

申请号：EP11710375.4

申请日：2011-03-15

申请人： Aventis Pharmaceuticals Inc.

发明人： HARRIS, Keith John ,  AGUIAR, Joacy C. ,  SHUM, Patrick Wai-Kwok ,  ZHAO, Zhicheng ,  POLI, Gregory B. ,  STOKLOSA, Gregory T. ,  CHOI-SLEDESKI, Yong-Mi ,  REILING, Stephan

IPC分类号： C07D403/04 ,  A61K31/505 ,  A61P11/00

CPC分类号： C07D403/04

摘要： The present invention is directed to a 2,6-substituted-4-monosubstitutedamino-pyrinudine compound of formula (I) as set forth herein, or an enantiomer thereof, or an ester prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such a compound. The invention also includes a method of treatment of a patient by the administration of a pharmaceutically effective amount of such a compound.